for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioNTech SE - ADR

22UAy.F

Latest Trade

87.99EUR

Change

0.40(+0.46%)

Volume

33,357

Today's Range

86.50

 - 

88.69

52 Week Range

19.10

 - 

102.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
87.59
Open
88.49
Volume
33,357
3M AVG Volume
66.26
Today's High
88.69
Today's Low
86.50
52 Week High
102.00
52 Week Low
19.10
Shares Out (MIL)
232.67
Market Cap (MIL)
25,272.85
Forward P/E
-95.30
Dividend (Yield %)
--

Latest Developments

更多

BioNTech And InstaDeep Announce Strategic Collaboration

Biontech And Fosun Pharma Announce Start Of Phase 2 Clinical Trial Of Lead mRNA Covid-19 Vaccine BNT162B2 In China

Pfizer And Biontech To Submit Emergency Use Authorization Request Today To U.S. FDA For COVID-19 Vaccine

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioNTech SE - ADR

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Industry

Biotechnology & Drugs

Contact Info

An der Goldgrube 12

55131

Germany

+49.6131.90840

https://biontech.de/

Key Stats

2.20 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2019

0.1K

2020(E)

0.4K
EPS (EUR)

2019

-0.850

2020(E)

-0.850
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
22.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
33.50
LT Debt To Equity (MRQ)
18.93
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

WRAPUP 1-India sees early vaccine launch as AstraZeneca deliveries run late

India raced ahead with work on its coronavirus vaccine while Britain's AstraZeneca said its deliveries were running "a little bit late" as countries around the world sought to conquer the pandemic and rescue their economies.

EXCLUSIVE-India-made COVID-19 vaccine could be launched as early as Feb - govt scientist

An Indian government-backed COVID-19 vaccine could be launched as early as February - months earlier than expected - as last-stage trials begin this month and studies have so far showed it is safe and effective, a senior government scientist told Reuters.

UPDATE 2-Australia orders more COVID-19 vaccines for total of 135 mln doses

The Australian government has agreed to purchase two more COVID-19 vaccines in development, beefing up the country's prospective arsenal against the pandemic to 135 million doses as it aims to complete a mass inoculation programme within months.

UPDATE 1-Chile, Peru green-light AstraZeneca COVID-19 vaccine trials

Chilean President Sebastian Pinera said on Wednesday the country's health regulator had given the go-ahead for clinical trials of AstraZeneca PLC's COVID-19 vaccine.

Australia signs two more COVID-19 vaccine deals

Australia signed two deals on Thursday to buy 40 million doses of COVID-19 vaccines from Novavax and 10 million from Pfizer and BioNTech as the country's virus hot spot reported zero cases for the sixth straight day.

EU drug watchdog won't set minimum efficacy levels for potential COVID-19 vaccines

Europe's drug regulator will not set a minimum level of efficacy for potential COVID-19 vaccines when considering them for approval, it said on Wednesday, taking a different approach to that of its U.S. counterpart.

UPDATE 4-Britain prepares for COVID-19 vaccine as Oxford forecasts result this year

* UK vaccine chief: slim chance will wipe out pandemic (Adds context, quotes, writes through)

UPDATE 1-China's Fosun to seek approval for BioNTech's COVID-19 second vaccine, ends trials on first

BioNTech's Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm's coronavirus vaccine candidate that has completed early-stage trials in China, an executive said.

China's Fosun to end BioNTech's COVID-19 vaccine trial, seek approval for another

BioNTech's Chinese partner Shanghai Fosun Pharmaceutical Group does not plan to run further clinical trials of the German firm's coronavirus vaccine candidate that has completed early-stage trials in China, an executive said.

UPDATE 1-CureVac's COVID-19 vaccine triggers immune response in Phase I trial

* Considering various options regarding vaccine partnership (Adds size of prospective Phase III trial, spokesman comment on dosage, possible partner)

CureVac's COVID-19 vaccine triggers immune response in Phase I trial

CureVac's experimental COVID-19 vaccine triggered an immune response in humans, it said on Monday, putting the German biotech company on track to start mass testing this year as the race to end the pandemic heats up.

UPDATE 2-J&J plans to test its COVID-19 vaccine in ages 12-18 soon

Johnson & Johnson plans to start testing its experimental COVID-19 vaccine in youths aged 12 to 18 as soon as possible, and the company's previous experience with the same technology in a vaccine successfully used in children could give it a leg up with regulators.

BioNTech CEO expects data from late-stage study soon

BioNTech Chief Executive Ugur Sahin expects efficacy results from its late-stage trial of its potential coronavirus vaccine to be available shortly and said the company could file for U.S. approval in mid-November if the data are positive.

UPDATE 4-Moderna on track to report late-stage COVID-19 vaccine data next month

Moderna Inc on Thursday said it is on track to report early data from a late-stage trial of its experimental COVID-19 vaccine next month, offering the clearest timeline yet for when the world will know whether it is effective.

Next crop of COVID-19 vaccine developers take more traditional route

The handful of drugmakers dominating the global coronavirus vaccine race are pushing the boundaries of vaccine technology. The next crop under development feature more conventional, proven designs.

UPDATE 1-Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's -Times

Senior sources in the British government expect that a verdict on whether Pfizer Inc-backed COVID-19 vaccine works will be available before the results are in on AstraZeneca Plc's competing vaccine, the Times reported.

Britain expects verdict on Pfizer's COVID-19 vaccine before AstraZeneca's -Times

Senior sources in the British government expect a verdict on whether Pfizer Inc and BioNTech SE's COVID-19 vaccine works will be available before AstraZeneca Plc's competing vaccine, the Times reported.

UPDATE 6-Pfizer says no COVID-19 vaccine data yet, could be week or more before it reports

Drugmaker Pfizer Inc said on Tuesday it does not yet have data from the late-stage trial of the COVID-19 vaccine it is developing with Germany's BioNTech SE , and provided a timeline that makes its release unlikely ahead of the Nov. 3 U.S. presidential election.

Pfizer CEO: may be a week between conclusive vaccine data, public notification

Pfizer Inc's Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE works, it could be a week before it lets the public know, making it unlikely it will release data before the Nov. 3 presidential...

Pfizer third-quarter sales fall 4.3% on pain drug weakness

Pfizer Inc on Tuesday reported a 4.3% drop in third-quarter sales, hurt by increased competition for its off-patent pain drug Lyrica and lower demand for some of its treatments during the COVID-19 pandemic.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up